Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma

Cancer Genetics and Cytogenetics

Volumn 118, Issue 2, 2000, Pages 89-98

  Simons, Annet ^a   Schepens, Marga ^a   Jeuken, Judith ^a   Sprenger, Sandra ^a   Van De Zande, Guillaume ^a   Bjerkehagen, Bodil ^b   Forus, Anne ^b   Weibolt, Vines ^a,c   Molenaar, Ineke ^c   Van Den Berg, Eva ^c   Myklebost, Ola ^b   Bridge, Julia ^d   Van Kessel, Ad Geurts ^a   Suijkerbuijk, Ron ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL CYCLE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; FEMALE; GENE AMPLIFICATION; GENE LOSS; GENOME; HUMAN; HUMAN TISSUE; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; PRIORITY JOURNAL; SOUTHERN BLOTTING;

BLOTTING, SOUTHERN; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; DENSITOMETRY; FEMALE; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; KARYOTYPING; MALE; NUCLEIC ACID HYBRIDIZATION; SOFT TISSUE NEOPLASMS;

EID: 0034656251     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(99)00178-8     Document Type: Article

References (49)

1. Weiss S.W., Enzinger F.M. Malignant fibrous histiocytoma. Cancer. 41:1978;2250-2266.
2. Enzinger F.M., Weiss S.W. Malignant fibrohistiocytic tumors. Enzinger F.M., Weiss S.W. Soft Tissue Tumors. 1995;351-380 C. V. Mosby Co, St. Louis.
3. Mandahl N., Heim S., Arheden K., Rydholm A., Willen H., Mitelman F. Rings, dicentrics, and telomeric associations in histiocytomas. Cancer Genet Cytogenet. 30:1988;23-33.
4. Mandahl N., Heim S., Willen H., Rydholm A., Eneroth M., Nilbert M., Kreicbergs A., Mitelman F. Characteristic karyotypic anomalies identify subtypes of malignant fibrous histiocytoma. Genes Chromosom Cancer. 1:1989;9-14.
5. Sandberg A.A., Bridge J.A. The Cytogenetics of Bone and Soft Tissue Tumors. 1994;R. G. Landes Company, Austin.
6. Heim S., Mitelman F. Cancer Cytogenetics. Chromosomal and Molecular Genetic Aberrations of Tumor Cells. 2nd Ed:1995;483 Wiley-Liss, New York.
7. Aspberg F., Mertens F., Brosjö O., Lindholm J., Mitelman F., Mandahl N. Near-haploidy in two malignant fibrous histiocytomas. Cancer Genet Cytogenet. 79:1995;119-122.
8. Szymanska J., Tarkkanen M., Wiklund T., Virolainen M., Blomqvist C., Asko-Seljavaara S., Tukiainen E., Elomaa I., Knuutila S. A cytogenetic study of malignant fibrous histiocytoma. Cancer Genet Cytogenet. 85:1995;91-96.
9. Walter T.A., Weh H.-J., Schlag P.M., Zornig C., Hossfeld D.K. Cytogenetic studies in malignant fibrous histiocytoma. Cancer Genet Cytogenet. 94:1997;131-134.
10. Schmidt H., Körber S., Hinze R., Taubert H., Meye A., Würl P., Holzhausen H.-J., Dralle H., Rath F.-W. Cytogenetic characterization of ten malignant fibrous histiocytomas. Cancer Genet Cytogenet. 100:1998;134-142.
11. Rydholm A., Mandahl N., Heim S., Kreicbergs A., Willen H., Mitelman F. Malignant fibrous histiocytomas with a 19p+ marker have increased relapse rate. Genes Chromosom Cancer. 2:1990;296-299.
12. Choong P.F.M., Mandahl N., Mertens F., Willen H., Mitelman F., Rydholm A. 19p+ marker chromosome correlates with relapse rate in malignant fibrous histiocytoma. Genes Chromosom Cancer. 16:1996;88-93.
13. Forus A., Olde Weghuis D., Smeets D., Fodstad Ø, Myklebost O., Geurts van Kessel A. Comparative genomic hybridization of human sarcomas. I. Occurence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas Genes Chromosom Cancer. 14:1995;8-14.
14. Larramendy M.L., Tarkkanen M., Blomqvist C., Viriolainen M., Wiklund T., Asko-Seljavaara S., Elomaa I., Knuutila S. Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. Am J Pathol. 151:1997;1153-1161.
15. Hinze R., Schagdarsurengin U., Taubert H., Meye A., Wurl P., Holzhausen H.J., Rath F.W., Schmidt H. Assessment of genomic imbalances in malignant fibrous histiocytomas by comparative genomic hybridization. Int J Mol Med. 3:1999;75-79.
16. Sakabe T., Shinomiya T., Mori T., Ariyama Y., Fukuda Y., Fujiwara T., Nakamura Y., Inazawa J. Identification of a novel gene, MASL1, within an amplicon at 8p23.1 detected in malignant fibrous histiocytomas by comparative genomic hybridization. Cancer Res. 59:1999;511-515.
17. Mairal A., Terrier P., Chibon F., Sastre X., Lecesne A., Aurias A. Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histiocytomas. A comparative genomic hybridization analysis of a series of 30 cases. Cancer Genet Cytogenet. 111:1999;134-138.
18. Kallioniemi A., Kallioniemi O.-P., Sudar D., Rutovitz D., Gray J.W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 258:1992;818-821.
19. Kallioniemi O.-P., Kallioniemi A., Piper J., Isola J., Waldman F., Gray J.W., Pinkel D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosom Cancer. 10:1994;231-243.
20. Knuutila S., Bjorkqvist A.M., Autio K., Tarkkanen M., Wolf M., Monni O., Szymanska J., Larramendy M.L., Tapper J., Pere H., El-Rifai W., Hemmer S., Wasenius V.M., Vidgren V., Zhu Y. DNA copy number amplifications in human neoplasms. review of comparative genomic hybridization studies Am J Pathol. 152:1998;1107-1123.
21. Ozaki T., Ikeda S., Kawai A., Inoue H., Oda T. Alterations of retinoblastoma susceptibility gene accompanied by c-MYC amplification in human bone and soft tissue tumors. Mol Cell Biol. 39:1993;235-242.
22. Wadayama B., Togushida J., Yamaguchi T., Sasaki M.S., Kotoura Y., Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer. 68:1993;1134-1139.
23. Wunder J.S., Czitrom A.A., Kandel R., Andrulis I.L. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl Cancer Inst. 83:1991;194-200.
24. Taubert H., Würl P., Meye A., Berger D., Thamm B., Neumann K., Hinze R., Schmidt H., Rath F.-W. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Cancer. 76:1995;1187-1196.
25. Nilbert M., Rydholm A., Mitelman F., Meltzer P.S., Mandahl N. Characterization of the 12q13-15 amplicon in soft tissue tumors. Cancer Genet Cytogenet. 83:1995;32-36.
26. Reid A.H., Tsai M.M., Venzon D.J., Wright C.F., Lack E.E., O'Leary T.J. MDM2 amplification, p53 mutation, and accumulation of the p53 gene product in malignant fibrous histiocytoma. Diagn Mol Pathol. 5:1996;65-73.
27. Berner J.-M., Meza-Zepeda L.A., Kools P.F.J., Forus A., Schoenmakers E.F.P.M., van de Ven W.J.M., Fodstad Ø, Myklebost O. HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene. 14:1997;2935-2941.
28. Forus A., Florenes V.A., Maelandsmo G.M., Meltzer P.S., Fodstad Ø, Myklebost O. Mapping of amplification units in the q13-14 region of chromosome 12. some amplica do not include MDM2 Cell Growth Differ. 4:1993;1065-1070.
29. Simons A., Janssen I.M., Suijkerbuijk R.F., Veth R.P.H., Pruszczynski M., Hulsbergen-van de Kaa C.A., du Manoir S., Geurts van Kessel A. Isolation of osteosarcoma-associated amplified DNA sequences using representational difference analysis. Genes Chromosom Cancer. 20:1997;196-200.
30. ISCN (1995): An International System for Human Cytogenetic Nomenclature. F Mitelman, ed. S. Karger, Basel.
31. Simons A, Schepens M, Forus A, Godager L, van Asseldonk M, Myklebost O, Geurts van Kessel A (in press): A novel chromosomal region of allelic loss, 4q32-34, in human osteosarcomas revealed by representational difference analysis. Genes Chromosom Cancer.
32. Jeuken JWM, Sprenger SHE, Wesseling P, Macville MVE, von Deimling A, Teepen HLJM, van Overbeeke JJ, Boerman RH (in press): Identification of subgroups of high grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol.
33. Karhu R., Kähkönen M., Kuukasjärvi T., Pennanen S., Tirkkonen M., Kallioniemi O. Quality control of CGH. impact of metaphase chromosomes and the dynamic range of hybridization Cytometry. 28:1997;198-205.
34. Simons A, Jeuken JWM, Eleveld MJ, Boerman RH, Geurts van Kessel A (in press): Isolation and characterisation of glioblastoma-associated homozygously deleted DNA fragments from chromosomal region 9p21 suggests involvement of multiple tumour suppressor genes. J Pathol.
35. dos Santos N.R., de Bruijn D.R.H., Balemans M., Janssen B., Gärtner F., Manuel Lopes J., de Leeuw B., Geurts van Kessel A. Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins. Hum Mol Genet. 6:1997;1549-1558.
36. Fung Y.-K.T., Murphree A.L., T'ang A., Qian J., Hinrich S.H., Benedict W.F. Structural evidence for the authenticity of the human retinoblastoma gene. Science. 236:1987;1657-1661.
37. Oliner J.D., Kinzler K., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83.
38. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day R.S. III, Johnson B.E., Skolnick M.H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
39. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
40. Mitelman F., Johansson B., Mertens F. Catalog of Chromosome Aberrations in Cancer '98. Version 1:1998;Wiley, CD-ROM.
41. Orndal C., Rydholm A., Willen H., Mitelman F., Mandahl N. Cytogenetic intratumor heterogeneity in soft tissue tumors. Cancer Genet Cytogenet. 78:1994;127-137.
42. Szymanska J., Virolainen M., Tarkkanen M., Wiklund T., Asko-Seljavaara S., Tukiainen E., Elomaa I., Blomqvist C., Knuutila S. Overrepresentation of 1q21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas. a comparative genomic hybridization study Cancer Genet Cytogenet. 99:1997;14-18.
43. Forus A., Berner J.-M., Meza-Zepeda L.A., Saeter G., Mischke D., Fodstad Ø, Myklebost O. Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas. Br J Cancer. 78:1998;495-503.
44. Maier D., Comparone D., Taylor E., Zhang Z., Gratzl O., van Meir E.G., Scott R.J., Merlo A. New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene. 15:1997;997-1000.
45. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanelli B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
46. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs W.B., Bova G.S., Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57:1997;4997-5000.
47. Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., Berchuck A., Futreal P.A. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 58:1998;2500-2503.
48. Zielenski J., Markiewicz D., Rininsland F., Rommens J., Tsui L.C. A cluster of highly polymorphic dinucleotide repeats in intron 17b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Am J Hum Genet. 49:1991;1256-1262.
49. Vysis (1996): Quips™ CGH Analysis User Guide, Version 2.0. Vysis.